Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, is a progressive neurological condition that gradually robs the body of voluntary muscle control. Because ALS moves quickly and demands a lot of specialized care, equipment, and drugs, how Medicare covers it matters enormously—and ALS is the rare diagnosis that gets its own special, fast-track path into Medicare. This guide explains that unique eligibility rule, what Medicare pays across drugs, breathing support, mobility equipment, and therapy, and where your largest out-of-pocket risks lie.

The Unique Rule: Medicare With No Waiting Period

For most people under 65, qualifying for Medicare through disability means a long wait: 24 months after Social Security Disability Insurance (SSDI) cash benefits begin. ALS is the major exception.

People diagnosed with ALS who are approved for SSDI get Medicare the same month their SSDI benefits begin—the 24-month waiting period is completely waived. (Since 2021, the separate five-month SSDI cash-benefit waiting period was also eliminated for ALS, so benefits and Medicare start much faster than for other conditions.)

This means a 55-year-old diagnosed with ALS can have full Medicare—Parts A, B, and D—within months, regardless of age. For the broader rules on disability-based Medicare, see our guide to Social Security disability benefits.

Once enrolled, an ALS beneficiary should make the same coverage decisions everyone else faces—Original Medicare with a supplement, or Medicare Advantage—covered below. Note that under-65 Medigap rights vary by state, which affects supplement options for younger ALS patients.

Doctor Visits, Multidisciplinary Clinics, and Therapy Under Part B

ALS care is best delivered by a coordinated team, and most of it runs through Part B at 80 percent after the $257 deductible (2026), leaving you 20 percent coinsurance:

  • Neurologist visits and multidisciplinary ALS clinic visits—neurology, pulmonology, physical/occupational/speech therapy, dietitian, and social work in one setting
  • Diagnostic testing—EMG, nerve conduction studies, MRI, and lab work to confirm the diagnosis and rule out mimics
  • Physical, occupational, and speech therapy—covered under Part B. There is no hard dollar cap; once spending passes the annual KX-modifier threshold, your therapist simply attests that continued therapy is medically necessary. Importantly, under the Jimmo v. Sebelius standard, therapy is covered to maintain function or slow decline—not only when you’re expected to improve, which is critical in a progressive disease.
  • Speech-generating devices (SGDs)—communication devices are covered as durable medical equipment when speech is impaired

Drugs: Oral (Part D) vs. Infused (Part B)

ALS drug therapy shows the familiar Medicare divide between pills you take at home and drugs given in a clinic—the same Part B vs. Part D split that drives cost across serious diagnoses.

Part D (home medications), capped at $2,000

  • Riluzole — the original oral ALS drug, now an inexpensive generic
  • Oral edaravone (Radicava ORS) — the at-home liquid form
  • Sodium phenylbutyrate/taurursodiol and other newer oral agents where prescribed
  • Symptom medications—for muscle cramps, spasticity, excess saliva, and the pseudobulbar affect drug Nuedexta

Under the 2025 Part D redesign, your total annual out-of-pocket for all covered Part D drugs is capped at $2,000, with the option to spread payments across the year via the Medicare Prescription Payment Plan. See our Part D guide for details. This cap matters because newer oral ALS agents carry very high list prices.

Part B (clinic-administered), no annual cap

  • Intravenous edaravone (Radicava IV) — given in cycles by infusion, billed under Part B at 20 percent coinsurance with no annual limit

As with other diagnoses, the IV version under Part B has no out-of-pocket ceiling, while the equivalent oral version under Part D is capped at $2,000. If both forms are clinically appropriate, it’s worth discussing the cost difference with your care team.

Breathing Support: A Central Part of ALS Coverage

Respiratory muscle weakness is the most serious aspect of ALS, and Medicare covers the equipment that supports breathing—mostly as durable medical equipment (DME) under Part B at 20 percent coinsurance:

  • Non-invasive ventilation (BiPAP/NIV) — often the single most important intervention for survival and comfort
  • Cough assist devices (mechanical insufflation-exsufflation) and suction machines
  • Invasive ventilators for those who choose tracheostomy ventilation
  • Supplemental oxygen when criteria are met

DME is generally rented or purchased through a Medicare-enrolled supplier; for items like ventilators, Medicare uses a frequent-and-substantial-servicing rental model. Your 20 percent coinsurance on this equipment, like all Part B coinsurance, has no annual cap under Original Medicare alone.

Mobility Equipment and Nutrition

  • Power wheelchairs and complex rehab power chairs, manual wheelchairs, walkers, hospital beds, patient lifts, and pressure-relief mattresses—covered as DME under Part B with documentation of medical need
  • Feeding tubes (PEG) and enteral nutrition—the tube placement is a Part B/Part A procedure, and the formula and supplies are covered as DME (enteral nutrition) under Part B when you cannot take adequate nutrition by mouth
  • What Medicare does NOT cover: home modifications such as wheelchair ramps, stair lifts, widened doorways, or roll-in showers—these are out-of-pocket or paid through other programs

Home Health, Hospitalization, and Hospice

  • Home health care—skilled nursing and therapy at home is covered at zero cost-sharing when you are homebound and need skilled care, a benefit ALS patients use heavily as the disease advances.
  • Hospitalization for respiratory crises or complications falls under Part A, subject to the $1,676 benefit-period deductible (2026).
  • The custodial-care gap—Medicare does not pay for long-term custodial care (help with bathing, dressing, eating) at home or in a facility when that is the only care needed. This is the biggest hidden cost in ALS. Funding it usually means long-term care insurance, personal assets, Medicaid, or VA benefits.
  • Hospice under Part A covers comfort-focused care—including drugs, equipment, nursing, and family support—at little to no cost when the focus shifts from cure to comfort.

Why Supplemental Coverage Is Decisive

ALS combines frequent Part B services (clinic visits, therapy, infused edaravone) with expensive DME (ventilators, power wheelchairs, feeding supplies)—all carrying uncapped 20 percent coinsurance under Original Medicare alone.

  • Medigap Plan G pays that 20 percent with no annual limit, so the BiPAP, the power wheelchair, and the infusion coinsurance leave you owing essentially only the small Part B deductible. See our Medigap plans guide. (Younger ALS patients should check their state’s under-65 Medigap rules.)
  • Medicare Advantage caps annual in-network out-of-pocket but adds prior authorization and network limits—a real concern when you need a specific ALS center, a particular DME supplier, or rapid approval for equipment as the disease progresses. Weigh the trade-offs in our Medicare Advantage vs. Original Medicare comparison and the cost-focused breakdown.

For a progressive disease that needs fast, flexible access to specialists and equipment, the predictability and open access of Original Medicare plus Plan G is often the safer choice—but the right answer depends on your finances and local plans.

Help With Costs

  • Extra Help (Low-Income Subsidy) sharply lowers Part D drug costs for those who qualify.
  • Medicare Savings Programs can pay your Part B premium and, at the QMB level, your Part B coinsurance—directly relieving the uncapped equipment and infusion exposure. See our Medicare Savings Programs guide.
  • The ALS Association and MDA offer equipment loan closets, clinic support, and financial navigation that complement Medicare.

The Bottom Line

ALS is the diagnosis Medicare treats most urgently: enrollment with no waiting period the moment SSDI begins. From there, Medicare covers the disease comprehensively—multidisciplinary clinics, therapy under the maintenance standard, oral and infused drugs, breathing and mobility equipment, home health, and hospice. The financial risks are the uncapped 20 percent coinsurance on heavy Part B and DME use, and the custodial-care gap Medicare doesn’t fill at all. Pairing Medicare with Medigap Plan G (where available) and tapping Extra Help, Medicare Savings Programs, and ALS-specific charities is what makes this demanding care affordable. For the wider picture of planning for serious illness in retirement, see our guide to healthcare costs in retirement.